Icon

QTERN (nda209091)- (5MG;EQ 5MG BASE,10MG;EQ 5MG BASE)

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ASTRAZENECA AB
5MG;EQ 5MG BASE,10MG;EQ 5MG BASE
Yes No
2030-Jun-16 2019-Jan-08
None None
None No
QTERN is a combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
0 5 0
Total Other Developers 5
Drugs with Suitability No
5MG;EQ 5MG BASE ** ** - - -
10MG;EQ 5MG BASE ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.